Apr 30, 2018 · 26m · a16z
Shifting Risk Mindsets, from Tech to Bio
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
This video features the a16z Bio team discussing essential business strategies, technical translations, and strategic pitfalls for founders building companies at the intersection of technology and biology. It outlines actionable insights on avoiding low-value pilot deals, structuring corporate entity models, and aligning hybrid investor syndicates.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. How this is scored →
The host as informed peer 3.2 Guest teaching 3.2 Guest disagreement 1.2 The host pushing back 1.7
speaking balance: gold is the host, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 7:24 Rejection of naive drug design pivots
Vijay forcefully highlights a critical founder delusion, noting that founders often pivot to drug design when pharma rejects their tech despite knowing nothing about designing drugs.
Hardest push from the host ▶ 17:12 Payer retention ROI challengeJorge directly challenges Vijay's point on diagnostics reimbursement by pointing out that rapid patient turnover makes early-screening ROI unappealing for insurance payers.
Biggest teaching moment ▶ 4:25 Value capture in preclinical assetsJeffrey articulates how value creation works in biotech, educating the panel on why service platforms fail to build sustainable businesses without owning drug candidates.
The host holds their own ▶ 18:38 Strategic payer pilot framingJorge synthesizes Vijay's reimbursement argument to propose an innovative strategy of running pilot projects directly with insurers to demonstrate ROI upfront.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | The host as informed peer | Guest teaching | Guest disagreement | The host pushing back | Why |
|---|---|---|---|---|---|---|
| High Bar of Proof and the Shift to Data-Driven Biotech | 3 | 3 | 1 | 1 | The participants engage in an agreeable round-table discussion regarding early proof-of-concept deals and the high bar of proof in bio. Vijay reframes AI as efficient data utilization, while Jorge highlights the risk of small pilot deals creating scope creep. | |
| Transitioning from Service Models to In-House Asset Development | 3 | 4 | 1 | 1 | Jeffrey explains how bio startups often begin as service providers before realizing value lies in developing in-house preclinical assets. Jorge agrees and elaborates on where companies fall in the value chain, noting pharma already has plenty of targets. | |
| The Risk of Unprepared Pivots into Drug Design | 3 | 4 | 2 | 2 | Vijay critically notes that tech founders often leap into drug design without knowing how to design drugs, presenting a dangerous pitfall. The group discusses strategic business development and novel parent-subsidiary LLC structures to protect core platform value. | |
| Generalizable Engineering Platforms and the Nimbus Case Study | 4 | 3 | 1 | 3 | The discussion covers platform validation through Nimbus case studies before shifting to diagnostics. Jorge offers constructive pushback to Vijay, questioning how diagnostics startups overcome short payer retention when seeking ROI on early screening. | |
| Synthetic Biology Commercialization and the 'Kill Experiment' | 3 | 3 | 1 | 2 | Jorge outlines productizing platform technologies using an Illumina-style model before turning to the existential necessity of conducting 'kill experiments'. The group agrees founders must prioritize experiments that could disprove their core thesis within 6 to 12 months. | |
| Investor Syndicates, Metrics, and Fluency in Tech and Bio | 3 | 2 | 1 | 1 | The panel explores fundraising dynamics across consumer, enterprise, and biotech verticals. Jorge details how building hybrid investor syndicates helps bridge fluency gaps between traditional tech and bio investors. |
Statements from this episode (18)
Lowe: Tech-bio founders struggle to translate tech for traditional audiences
“I think it's about speaking a new language. So you have, you know, tech entrepreneurs and technical founders coming in and speaking a language. That is very geared toward a tech audience having a new technology, and I think what we're so interested in is bring…”
Pande: Small tech-bio pilot deals sound much more impressive than they are
“You could get early proof of concept deals, and that will look good. You might have, like, five deals, and it'll be, like, a couple hundred K each. But in reality, those are so easy to get that it's, maybe it sounds more impressive than it is.”
Pande: Biotechs and pharma will eventually become data science companies
“People point to AI and machine learning, but really that's, I think, just a surrogate for the fact that data is being used very efficiently, and we have so much more data, and we do have techniques that actually didn't exist before, but in many ways it's, ah, …”
Conde: Bio startup pilot projects often take twice as long as expected
“If you were, you thought you would finish pilot, you know, a pilot project and get paid X in Y amount of time, oftentimes you're getting paid X in something like two X, two times the Y amount of time, and you're also working a lot harder if there's been scope …”
Lowe: Tech-bio service pilot models fail to generate sustainable economics
“And they start as a service company. They start by saying, hey, I'm gonna go to big pharma. I have a new techno, technological breakthrough. I'm gonna sell that as a pilot to, as a service to big pharma companies. And then they can't generate the economics tha…”
Lowe: Preclinical bio assets lack significant value until reaching clinical trials
“That is because in the bio space value is created in these huge technical milestones in the very beginning where a lot of these services are used. These are preclinical assets in which there's really not too much value until you bring a drug candidate into the…”
Conde: Pharma companies are swimming in targets but lack pipeline drugs
“Pharma companies are swimming in targets, right? The problem they're trying to solve for is how do I fill in my pipeline?”
Conde: Platforms focused solely on target discovery struggle to capture value
“And so if your platform is to identify novel targets, it's going to actually be very hard. That's sort of the end of the line for what your technology can do. It's really hard to capture value there. And certainly hard to get that from a collaboration standpoi…”
Pande: Bio startups risk failure pivoting to drug design without internal expertise
“Whatever the technology is, they got the cool technology, they think this will change drug design, and so then they go to pharma and they try to sell it. And pharma's not convinced yet. Ah, it's like my kids with new foods, and they don't want to try it until …”
Conde: Skilled business development teams bridge a fatal chasm for bio startups
“Business development in the bio space is a fundamentally strategic advantage to have. If you have a team that is good at structuring business development deals, in other words, that has experience in the space, that allows you to actually help bridge what is o…”
Conde: Successful drug assets routinely starve underlying biotech platforms of resources
“All of the conversations start to focus on, well, we could always use more resources on making sure that the drug program succeeds, and there's only a fixed pool of resources, generally speaking, and so what ends up happening is the platform Get Start, and I t…”
Lowe: Unvalidated biotech platforms carry little value until an asset proves efficacy
“A unvalidated platform really doesn't have a lot of value, and that's why there's, On the first asset, you know, the whole company's value may be riding on this asset because not only is that asset in itself valuable, but it also validates the efficacy and use…”
Pande: Reimbursement is a bigger hurdle for diagnostics startups than FDA approval
“Ironically, I think, you know, most people think about the FDA or CLIA being your big, ah, concern. I think reimbursement's probably the first place to start, because I wouldn't want to sort of be designing a test without having the confidence that I'll get re…”
Pande: Self-insured employers are optimal early reimbursement targets for screening diagnostics
“Self-insured employers might be a little more motivated because while people may change plans, they change jobs slightly less frequently.”
Conde: Bio platforms should target high-end research institutions before expanding down-market
“And you sell to the high end of the market first, right? So what, you know, what we saw with happening with sequencing was that obviously in the very early days when, you know, the throughput of the sequencer It was low, where the cost was very high. The only …”
Conde: Bio entrepreneurs must prioritize and execute early killer experiments
“If you're developing technology in the biology space, you should know what your near term killer experiment is. And the experiment that if it does not work, It's, you know, kill mode for whatever you're developing. And you should know what that is. You should …”